At the 2026 IFCPC Congress, Prof. Elena Ratner from Yale School of Medicine shared her insights on the evolving management of cervical precancer.
For young women with CIN2, treatment decisions are moving beyond a simple choice between observation and excisional surgery. While LEEP and cone biopsy remain important options, they may also affect cervical integrity and future pregnancy outcomes.
Cevira®/HAL-PDT, a topical non-invasive photodynamic therapy, offers a tissue-preserving option between watchful waiting and surgery. In the Phase III APRICITY study, Cevira® achieved a 57.5% pathological regression/downgrading rate in CIN2 patients at 6 months after 1–2 treatments, with encouraging HPV16/18 clearance at 12 months.
Cevira® is not simply replacing surgery. It may help reshape CIN2 care into a more individualized pathway: observation, non-invasive treatment, and excision when needed.
From treating disease to protecting fertility and quality of life, CIN2 management is entering a new era.